Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

CDK4/6 inhibitors in combination with endocrine therapy has shown efficacy in ER + breast cancer patients but resistance can occur. Here, the authors demonstrate that co-targeting CDK4/6 and AKT with endocrine therapy prevents acquired resistance and therapy adaptation.

Guardado en:

Detalles Bibliográficos
Autores principales:	Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd L. Gammelgaard, Monique F. Hundebøl, Kamila Kaminska, Lene E. Johansen, Martin Bak, Gabriella Honeth, Ana Bosch, Elgene Lim, Henrik J. Ditzel
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/73e69d21bd364412a70101afb76ad7da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:73e69d21bd364412a70101afb76ad7da
record_format	dspace
spelling	oai:doaj.org-article:73e69d21bd364412a70101afb76ad7da2021-12-02T16:35:13ZCo-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer10.1038/s41467-021-25422-92041-1723https://doaj.org/article/73e69d21bd364412a70101afb76ad7da2021-08-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-25422-9https://doaj.org/toc/2041-1723CDK4/6 inhibitors in combination with endocrine therapy has shown efficacy in ER + breast cancer patients but resistance can occur. Here, the authors demonstrate that co-targeting CDK4/6 and AKT with endocrine therapy prevents acquired resistance and therapy adaptation.Carla L. AlvesSidse EhmsenMikkel G. TerpNeil PortmanMartina TuttolomondoOdd L. GammelgaardMonique F. HundebølKamila KaminskaLene E. JohansenMartin BakGabriella HonethAna BoschElgene LimHenrik J. DitzelNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Carla L. Alves Sidse Ehmsen Mikkel G. Terp Neil Portman Martina Tuttolomondo Odd L. Gammelgaard Monique F. Hundebøl Kamila Kaminska Lene E. Johansen Martin Bak Gabriella Honeth Ana Bosch Elgene Lim Henrik J. Ditzel Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
description	CDK4/6 inhibitors in combination with endocrine therapy has shown efficacy in ER + breast cancer patients but resistance can occur. Here, the authors demonstrate that co-targeting CDK4/6 and AKT with endocrine therapy prevents acquired resistance and therapy adaptation.
format	article
author	Carla L. Alves Sidse Ehmsen Mikkel G. Terp Neil Portman Martina Tuttolomondo Odd L. Gammelgaard Monique F. Hundebøl Kamila Kaminska Lene E. Johansen Martin Bak Gabriella Honeth Ana Bosch Elgene Lim Henrik J. Ditzel
author_facet	Carla L. Alves Sidse Ehmsen Mikkel G. Terp Neil Portman Martina Tuttolomondo Odd L. Gammelgaard Monique F. Hundebøl Kamila Kaminska Lene E. Johansen Martin Bak Gabriella Honeth Ana Bosch Elgene Lim Henrik J. Ditzel
author_sort	Carla L. Alves
title	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
title_short	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
title_full	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
title_fullStr	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
title_full_unstemmed	Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
title_sort	co-targeting cdk4/6 and akt with endocrine therapy prevents progression in cdk4/6 inhibitor and endocrine therapy-resistant breast cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/73e69d21bd364412a70101afb76ad7da
work_keys_str_mv	AT carlalalves cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT sidseehmsen cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT mikkelgterp cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT neilportman cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT martinatuttolomondo cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT oddlgammelgaard cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT moniquefhundebøl cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT kamilakaminska cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT leneejohansen cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT martinbak cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT gabriellahoneth cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT anabosch cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT elgenelim cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer AT henrikjditzel cotargetingcdk46andaktwithendocrinetherapypreventsprogressionincdk46inhibitorandendocrinetherapyresistantbreastcancer
_version_	1718383697652088832

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Ejemplares similares